EBITDA for Incyte (INCY)
According to Incyte's latest reported financial statements, the company's current EBITDA (TTM) is $1.80B USD. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
INCY
Currently viewingEBITDASwitch metric
TTM (last 4 quarters)
$1.80B
YoY change
+331.2%
5Y CAGR
N/A
Peak year (2025)
$1.76B
Cumulative EBITDA
$3.98B
EBITDA history chart for Incyte (INCY) from 1993 to 2025
EBITDA history table for Incyte (INCY) from 1993 to 2025
| Fiscal year | Period ended | Reported | EBITDA | YoY |
|---|---|---|---|---|
| 2025 | $1.76B | +331.2% | ||
| 2024 | $408.16M | -55.6% | ||
| 2023 | $919.43M | +53.3% | ||
| 2022 | $599.64M | -4.8% | ||
| 2021 | $630.20M | -453.6% | ||
| 2020 | -$178.24M | -132.8% | ||
| 2019 | $543.18M | +216.1% | ||
| 2018 | $171.86M | -167.9% | ||
| 2017 | -$253.21M | -223.8% | ||
| 2016 | $204.57M | +108.7% | ||
| 2015 | $98.04M | +145.4% | ||
| 2014 | $39.96M | -366.6% | ||
| 2013 | -$14.99M | -147.0% | ||
| 2012 | $31.89M | -127.6% | ||
| 2011 | -$115.73M | -421.8% | ||
| 2010 | $35.96M | -122.1% | ||
| 2009 | -$163.06M | +15.7% | ||
| 2008 | -$140.91M | +182.5% | ||
| 2007 | -$49.89M | +2.1% | ||
| 2006 | -$48.84M | -38.7% | ||
| 2005 | -$79.67M | -39.7% | ||
| 2004 | -$132.06M | -11.5% | ||
| 2003 | -$149.30M | +35.1% | ||
| 2002 | -$110.52M | +548.8% | ||
| 2001 | -$17.03M | -38.6% | ||
| 2000 | -$27.75M | +1106.4% | ||
| 1999 | -$2.30M | -107.7% | ||
| 1998 | $30.00M | +114.3% | ||
| 1997 | $14.00M | -683.3% | ||
| 1996 | -$2.40M | -70.4% | ||
| 1995 | -$8.10M | -27.7% | ||
| 1994 | -$11.20M | +148.9% | ||
| 1993 | -$4.50M | — |
EBITDA values are taken from Incyte's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
As of the 2025 fiscal year, Incyte (INCY) reported EBITDA of $1.76B – surged 331.2% year-over-year.
Through 2015–2025 (10 years), Incyte EBITDA delivered a +33.5% annualised rate; with the latest reading among the more recent periods of the dataset.
The highest annual EBITDA of $1.76B was reported in 2025. The lowest in the available history was -$253.21M in 2017.
Within Healthcare, Incyte (INCY) ranks 9th among 8 peers we track. The peer median for EBITDA is $24.21B.
Incyte EBITDA by Year
Incyte EBITDA 2025: $1.76B
Incyte EBITDA in 2025 was $1.76B, surged 331.2% from 2024. This figure represents the highest annual value in the available history.
Incyte EBITDA 2024: $408.16M
Incyte EBITDA in 2024 was $408.16M, plunged 55.6% below 2023.
Incyte EBITDA 2023: $919.43M
Incyte EBITDA in 2023 was $919.43M, surged 53.3% from 2022.
Incyte EBITDA 2022: $599.64M
Incyte EBITDA in 2022 was $599.64M, edged down 4.8% below 2021.
Incyte EBITDA 2021: $630.20M
Incyte EBITDA in 2021 was $630.20M.
See more financial history for Incyte (INCY).
Sector peers — EBITDA
Companies in the same sector as Incyte, ranked by their latest EBITDA.
| Company | EBITDA | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $156.73B | Healthcare |
| Johnson & Johnson (JNJ) | $41.05B | Healthcare |
| Eli Lilly and Company (LLY) | $27.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $25.36B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $23.06B | Healthcare |
| AstraZeneca PLC (AZN) | $19.83B | Healthcare |
| AbbVie Inc. (ABBV) | $17.63B | Healthcare |
| Amgen Inc. (AMGN) | $15.84B | Healthcare |
Frequently asked questions
What is Incyte's EBITDA?
- Latest reported EBITDA for Incyte (INCY) is $1.80B (period ending March 31, 2026).
How has Incyte EBITDA changed year-over-year?
- Incyte (INCY) EBITDA changed +331.2% year-over-year on the latest annual filing.
What is the long-term growth rate of Incyte EBITDA?
- Incyte (INCY) EBITDA compound annual growth rate is +33.5% over the most recent 10 years available.
When did Incyte EBITDA hit its highest annual value?
- Incyte EBITDA reached its highest annual value of $1.76B in 2025.
What was Incyte EBITDA in 2024?
- Incyte (INCY) EBITDA in 2024 was $408.16M.
What was Incyte EBITDA in 2025?
- Incyte (INCY) EBITDA in 2025 was $1.76B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
INCY Overview
Company profile, financial tools, and key metrics
INCY Revenue Counter
Earns $163.03 every second. See per minute, hour, and day.
INCY Earnings Counter
Earns $40.80 per second net profit. See per minute, hour, and day.
INCY Economic Scale
Exceeds Eswatini's GDP. Compare with world economies.
INCY What If Invested
What if you had invested $1,000? See historical returns from any date.
INCY How It Makes Money
Discover visual breakdown of $5.14B in revenue — where it comes from and where it goes.
INCY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
INCY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
INCY Daily Price Character
Explosive · 48.3% historical win rate (green days). Streaks & record days.
INCY Buybacks
0.10% TTM buyback yield. Shareholder yield & SBC comparison.
INCY Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.